EC Number   |
Inhibitors |
Structure |
|---|
    1.1.1.25 | (azepan-1-yl)(3-methyl-4,5-dinitrophenyl)methanone |
- |
   |
| 1.1.1.25 | 1,2,4-triazolo[3,4-b][1,3,4]thiadiazole |
half-maximal inhibition at 0.023 mg/ml |
|
| 1.1.1.25 | 1,3-benzodioxole-5-carbothioamide |
the compound shows higher affinity for the shikimate binding site than for the NADP+ binding site, mixed full inhibition mechanism versus shikimate, non-competitive full inhibition mechanism versus NADP+, interaction analysis and enzyme-bound structure, overview. 75% inhibition at 0.4 mM |
|
| 1.1.1.25 | 2,2'-bithiophene-5-carboxylic acid |
the inhibitor is identified by virtual screeening, 87% inhibition at 0.2 mM, competitive versus shikimate, uncompetitive versus NADP+. Flexible docking studies reveal that the inhibitor molecule makes interactions with catalytic residues |
|
| 1.1.1.25 | 2,2-bisepigallocatechin gallate |
about 50% inhibition at 0.0025 mM |
|
| 1.1.1.25 | 2,4-Dichlorophenoxyacetic acid |
- |
|
| 1.1.1.25 | 2,5-dimethyl-1,4-phenylene bis(trifluoroacetate) |
- |
|
| 1.1.1.25 | 2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol |
- |
|
| 1.1.1.25 | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl 6-deoxy-alpha-L-mannopyranoside |
- |
|
| 1.1.1.25 | 2-(3,4-dihydroxyphenyl)ethyl 6-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranoside |
- |
|
